Estrogen-responsive reporter activation and antagonist control
Cell-based study · ER-positive human MCF-7 breast cancer cells [1]
Zearalenone increased ERE-dependent reporter activity. ICI182,780 reduced the response, supporting involvement of estrogen receptors without establishing isoform selectivity or direct binding affinity.
| Endpoint | Reported result | Reference |
|---|---|---|
| ERE-TK-luciferase activity normalized to the estradiol response | Reported concentration-response Significant activation starting at 10⁻⁹ M (Results 3.1: p < 0.01); maximum within the tested range reported at 10⁻⁸ M. | [1] |
| Response to 10⁻⁸ M zearalenone with or without 10⁻⁶ M ICI182,780 | Antagonist control ICI182,780 reduced zearalenone-stimulated luciferase activity; no bar-derived exact value assigned. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10⁻¹¹–10⁻⁶ M zearalenone concentration series; antagonist comparison: 10⁻⁸ M zearalenone ± 10⁻⁶ M ICI182,780.
- Exposure duration
- 24 h for concentration-response experiments.
- Method
- Exposure of transfected, steroid-deprived MCF-7 cells.
- Vehicle
- Solvent control reported; solvent identity/concentration not specified in the selected assay methods.
- Co-treatment
- ICI182,780 cotreatment is a mechanistic control; estradiol is a separate positive control.
- Reported limits
- No EC50 or direct-binding measurement reported for this selected experiment. Figure 1D replication is not separately specified in the caption.
Methods and source locations
Compound reported in the paper: Zearalenone; Compound label in the paper: Zearalenone
Results apply to the reported zearalenone reagent and cellular model; no product-lot validation.
Methods 2.1–2.2, 2.8; Results 3.1; Figure 1A,D and caption
ERE-TK-luciferase activity normalized to the estradiol response: Luciferase reporter; CMV-β-galactosidase transfection control; solvent negative control and 10⁻⁹ M estradiol positive control. Figure 1A: means ± SEM of 3–4 independent experiments. — Methods 2.1–2.2, 2.8; Results 3.1; Figure 1A and caption
Response to 10⁻⁸ M zearalenone with or without 10⁻⁶ M ICI182,780: ERE reporter with antiestrogen cotreatment, compared with the corresponding treatment without antagonist. — Methods 2.2; Results 3.1; Figure 1D and caption